The impact of STAS on recurrence-free and overall survival in T1-2N0 adenocarcinomas: a single-center retrospective study
- 1Department of Thoracic Surgery, Ankara University Faculty of Medicine
- 2Department of Statistics, Hacettepe University Faculty of Science
- 3Department of Medical Pathology, Ankara University Faculty of Medicine
Abstract
Background Adenocarcinoma (AC) is the leading histopathological type of lung cancer (LC), curative surgery being the cornerstone for the best survival results. However, even in the patients who had curative surgery, the survival outcomes differ. Spread through air spaces (STAS), recognized as a histopathological feature in the 2015 World Health Organization (WHO) Classification, causes poor survival outcomes in lung AC. This study aimed to evaluate the prognostic impact of STAS on recurrence-free survival (RFS) and overall survival (OS) in surgically resected T1-2N0 lung AC, with particular attention to its interaction with tumor size. Methods This single center retrospective study evaluates the effect of STAS on RFS and OS in 296 surgically resected T1-2N0 lung AC patients. For further analysis, patients were divided into four subgroups combining their STAS status and tumor size. Results STAS presence rate was 37.5%, which was associated with aggressive tumor characteristics, such as non-lepidic predominant subtypes, higher pathological T stage (pT), visceral pleura invasion (VPI), and lymphovascular invasion (LVI). OS and RFS were significantly worse in the STAS-Present (STAS-P) group (p = 0.030). Subgroup analysis revealed that STAS-P tumors > 2 cm had the worst outcomes, as expected. Notably, on univariate analysis STAS presence appeared most prognostically decisive in tumors ≤ 2 cm, in which there was no significant difference in survival between STAS-P tumors ≤ 2 cm and STAS-Absent (STAS-A) tumors > 2 cm. Conclusions STAS was a significant prognostic factor on univariate analysis but did not retain independent significance after multivariable adjustment. In an exploratory subgroup analysis, STAS-P tumors ≤ 2 cm carried survival outcomes comparable to STAS-A tumors > 2 cm, suggesting STAS may attenuate the prognostic advantage of smaller tumor size. This hypothesis-generating finding warrants prospective validation before informing surgical management. Graphical Abstract
Related
- The impact of extranodal spread on overall and recurrence-free survival in patients with clinically early-stage cervical cancer, but with tumor positive pelvic lymph nodes after radical hysterectomy
- Prognostic impact of the preoperative Naples prognostic score on overall and progression-free survival in surgically treated oral squamous cell carcinoma: A retrospective cohort study from a Taiwanese medical center.
- Complete necrosis of HCC improves recurrence-free and overall survival after transplantation independent of baseline risk
- Peripheral Lymphocyte Subsets Predict Efficacy and Overall Survival in Gastric Cancer Patients Receiving Preoperative Chemotherapy: A Retrospective Cohort Study
- Lower lung donor PaO2/FiO2 ratio correlates with early primary graft dysfunction, but does not impact overall survival after lung transplantation: a dual center study
BibTeX
@article{dursun2026impact,
title = {{The impact of STAS on recurrence-free and overall survival in T1-2N0 adenocarcinomas: a single-center retrospective study}},
author = {Şebnem Dursun and Saliha Yılmaz and Yusuf Kahya and Gökhan Kocaman and Süleyman Gökalp Güneş and Duru Karasoy and Serkan Enön and Serpil Dizbay Sak and Ayten Kayı Cangır},
journal = {BMC Cancer},
year = {2026},
month = jul,
doi = {10.1186/s12885-026-16623-w},
url = {https://doi.org/10.1186/s12885-026-16623-w},
note = {CC BY},
}
RIS
TY - JOUR
TI - The impact of STAS on recurrence-free and overall survival in T1-2N0 adenocarcinomas: a single-center retrospective study
AU - Şebnem Dursun
AU - Saliha Yılmaz
AU - Yusuf Kahya
AU - Gökhan Kocaman
AU - Süleyman Gökalp Güneş
AU - Duru Karasoy
AU - Serkan Enön
AU - Serpil Dizbay Sak
AU - Ayten Kayı Cangır
PY - 2026
DA - 2026/07/01
JO - BMC Cancer
DO - 10.1186/s12885-026-16623-w
UR - https://doi.org/10.1186/s12885-026-16623-w
AB - Background Adenocarcinoma (AC) is the leading histopathological type of lung cancer (LC), curative surgery being the cornerstone for the best survival results. However, even in the patients who had curative surgery, the survival outcomes differ. Spread through air spaces (STAS), recognized as a histopathological feature in the 2015 World Health Organization (WHO) Classification, causes poor survival outcomes in lung AC. This study aimed to evaluate the prognostic impact of STAS on recurrence-free survival (RFS) and overall survival (OS) in surgically resected T1-2N0 lung AC, with particular attention to its interaction with tumor size. Methods This single center retrospective study evaluates the effect of STAS on RFS and OS in 296 surgically resected T1-2N0 lung AC patients. For further analysis, patients were divided into four subgroups combining their STAS status and tumor size. Results STAS presence rate was 37.5%, which was associated with aggressive tumor characteristics, such as non-lepidic predominant subtypes, higher pathological T stage (pT), visceral pleura invasion (VPI), and lymphovascular invasion (LVI). OS and RFS were significantly worse in the STAS-Present (STAS-P) group (p = 0.030). Subgroup analysis revealed that STAS-P tumors > 2 cm had the worst outcomes, as expected. Notably, on univariate analysis STAS presence appeared most prognostically decisive in tumors ≤ 2 cm, in which there was no significant difference in survival between STAS-P tumors ≤ 2 cm and STAS-Absent (STAS-A) tumors > 2 cm. Conclusions STAS was a significant prognostic factor on univariate analysis but did not retain independent significance after multivariable adjustment. In an exploratory subgroup analysis, STAS-P tumors ≤ 2 cm carried survival outcomes comparable to STAS-A tumors > 2 cm, suggesting STAS may attenuate the prognostic advantage of smaller tumor size. This hypothesis-generating finding warrants prospective validation before informing surgical management. Graphical Abstract
SN - 1471-2407
ER -